Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202506097 An Investigator-Initiated Study on the Effects of Tocilizumab on Body Composition in Rheumatoid Arthritis Patients with High-Risk Sarcopenia New Drug Phase Ⅳ
N202506098 A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event New Drug Phase Ⅲ
N202506107 A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) New Drug Phase Ⅲ
N202506128 Using thermal imaging to detect subcutaneous tissue changes and reduce damage when contrast agent leaks
SHH / Yi-Hsien Lin
New Medical Device NA
N202507001 A Multicenter, Open label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab New Drug Phase Ⅲ
N202507002 A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-902 in Participants with Advanced Solid Tumors New Drug Phase Ⅰ
N202507023 Clinical trial of new anti-acne patches (2) New Medical Device NA
N202507031 Developing and Validating an AI-Driven Digital Therapeutic Application for Insomnia New Medical Device NA
1 2 28 29 30 31 32 33 34 51 52 / 52

TOP